Current Vascular Pharmacology
Title:Meet Our Editorial Board Member
Volume: 17 Issue: 2
Author(s): Laurent Metzinger
Affiliation:
Export Options
About this article
Cite this article as:
Metzinger Laurent , Meet Our Editorial Board Member, Current Vascular Pharmacology 2019; 17 (2) . https://dx.doi.org/10.2174/157016111702181219145334
DOI https://dx.doi.org/10.2174/157016111702181219145334 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Genetic and Molecular Determinants of Atherosclerotic Plaque Instability
Current Vascular Pharmacology Targets for the Treatment of Erectile Dysfunction: Is NO/cGMP Still the Answer?
Recent Patents on Cardiovascular Drug Discovery Withdrawal Notice: Ionic Liquid Mediated Synthesis of Schiff bases Bearing Thiazole and Indole Moieties
Current Organic Synthesis Analysis of Contrast-Enhanced Intravascular Ultrasound Images for the Assessment of Coronary Plaque Neoangiogenesis: Another Step Closer to the Identification of the Vulnerable Plaque
Current Pharmaceutical Design Matrix Metalloproteinases and their Tissue Inhibitors in Diabetes, Atherosclerosis and Prediction of the Cardiovascular Risk
Current Enzyme Inhibition Role of Salt and Potassium in Hypertension and the Associated Organ Damages
Current Hypertension Reviews Sodium-glucose Cotransporter 2 Inhibitors and the Risk of Diabetic Ketoacidosis; from Pathophysiology to Clinical Practice
Cardiovascular & Hematological Disorders-Drug Targets Targeting Ion Channels in Leukemias: A New Challenge for Treatment
Current Medicinal Chemistry Reductions in Medications with Substantial Weight Loss with Behavioral Intervention
Current Clinical Pharmacology Increased Pulmonary Heme Oxygenase-1 and δ-Aminolevulinate Synthase Expression in Monocrotaline-Induced Pulmonary Hypertension
Current Neurovascular Research Obesity Promotes Oxidative Stress and Exacerbates Sepsis-induced Brain Damage
Current Neurovascular Research Colloid Update
Current Pharmaceutical Design Drotrecogin Alfa (Activated) in the Treatment of Severe Sepsis
Current Drug Safety Diabetes Exacerbates Nanoparticles Induced Brain Pathology
CNS & Neurological Disorders - Drug Targets Prothrombotic Potential of NSAID in Ischemic Heart Diesase
Mini-Reviews in Medicinal Chemistry NLRP3 Inflammasome Activation Leads to Epileptic Neuronal Apoptosis
Current Neurovascular Research In Vitro Modeling of the Blood-Brain Barrier: Simplicity Versus Complexity
Current Pharmaceutical Design Generic Clopidogrel Besylate in the Secondary Prevention of Atherothrombotic Events: A 6-month Follow-up of a Randomised Clinical Trial
Current Vascular Pharmacology Nuclear Receptors as Potential Molecular Targets in Cholesterol Accumulation Conditions: Insights from Evidence on Hepatic Cholesterol Degradation and Gallstone Disease in Humans
Current Medicinal Chemistry Leukocyte Adhesion: A Suitable Target for Anti-Inflammatory Drugs
Current Pharmaceutical Design